What question did this study set out to answer?

Review the underlying pathophysiology, prophylactic strategies, and pharmacologic therapies for managing the no-reflow phenomenon following reperfusion therapy.

January 1, 2008Acute Cardiac Care

Management of ‘no‐reflow’ complicating reperfusion therapy

View Full Paper

Ask AI

Bookmark

Population

Patients experiencing no-reflow phenomenon following reperfusion therapy for acute myocardial infarction or…

Design

Review

Authors

KLKaeng W. LeeWolverhampton Hospital MNM S NorellUniversity of Wolverhampton

Discussion

Member takes

Implication

May support adjunctive use in no-reflow during PCI; leaves open need for randomized confirmation of outcomes.

Key Points

Review the underlying pathophysiology, prophylactic strategies, and pharmacologic therapies for managing the no-reflow phenomenon following reperfusion therapy.
Synthesis of clinical evidence evaluating mechanisms of microvascular obstruction during percutaneous coronary intervention (PCI) and thrombolysis.
Evaluation of intracoronary vasodilators and mechanical distal embolic protection devices used in acute myocardial infarction and saphenous vein graft interventions.
Atheromatous embolization and intense arteriole vasospasm induced by platelet-rich microthrombi drive microvascular obstruction and impaired perfusion.
Intracoronary administration of verapamil, adenosine, and nitroprusside improves epicardial flow and microvascular perfusion during PCI for acute myocardial infarction or saphenous vein graft lesions.
Distal embolic protection devices provide microvascular protection and improve outcomes in saphenous vein graft procedures, though prevention remains critical because established no-reflow is often irreversible.

Structured PICO

Population

Patients experiencing no-reflow phenomenon following reperfusion therapy (thrombolysis or percutaneous coronary interventions) for acute myocardial infarction or saphenous vein graft (SVG) lesions

Intervention

Intracoronary verapamil, adenosine, nitroprusside, and distal embolic protection devices

Outcome

Epicardial flow, microvascular perfusion, and clinical outcomes

Prevention and anticipation are the most critical measures for managing no-reflow during PCI, alongside pharmacological and mechanical interventions.

Cite This Study

Lee et al. (2008) studied this question.

synapsesocial.com/papers/6a78b6a5de5e3adfbdf79700 https://doi.org/10.1080/17482940701744318

View Full Paper

Ask AI

Bookmark